K.J. Harrison & Partners Inc Has $2.46 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

K.J. Harrison & Partners Inc grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 104.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,091 shares of the biopharmaceutical company’s stock after purchasing an additional 2,090 shares during the period. K.J. Harrison & Partners Inc’s holdings in Regeneron Pharmaceuticals were worth $2,455,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $31,000. Traub Capital Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $38,000. Berbice Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 35 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of recent research reports. Wells Fargo & Company lifted their price target on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. HSBC started coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $255.00 target price on the stock. Citigroup increased their price target on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Canaccord Genuity Group raised their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Finally, Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $793.81.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 5,274 shares of company stock worth $4,142,738 in the last 90 days. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $784.28 on Thursday. The stock has a market capitalization of $82.91 billion, a price-to-earnings ratio of 18.87, a P/E/G ratio of 2.07 and a beta of 0.40. The firm’s 50-day moving average price is $770.88 and its two-hundred day moving average price is $678.50. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue was up 2.5% on a year-over-year basis. During the same period last year, the firm posted $12.07 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be issued a $0.94 dividend. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approved Dupixent for allergic fungal rhinosinusitis (AFRS) in patients aged 6+, marking the drug’s ninth U.S. indication and addressing a hard-to-treat sinus disease; approval is supported by Phase 3 data showing symptom reduction and lower need for steroids or repeat surgery, boosting Dupixent’s long-term revenue potential. GlobeNewswire: Dupixent approved for AFRS
• Positive Sentiment: Regeneron and Sanofi announced the same FDA approval in commercial/press coverage highlighting strong Phase 3 data and broader market adoption potential for Dupixent across sino-nasal and type 2 inflammatory diseases. Yahoo: Dupixent AFRS coverage
• Positive Sentiment: The FDA accepted Regeneron’s BLA for garetosmab under Priority Review for fibrodysplasia ossificans progressiva (FOP), accelerating the regulatory timeline for a potential new orphan indication and adding near-term pipeline value if approved. Yahoo: FDA accepts garetosmab BLA
• Positive Sentiment: Analyst and media bullish takes (e.g., The Motley Fool) highlight Regeneron’s product depth, manufacturing capabilities and combined commercial strength with Sanofi as reasons the stock could outperform long-term — supportive commentary that can sustain investor interest after the approval news. Fool: Reasons REGN could outperform
• Neutral Sentiment: Market commentary is flagging short-term price cooling and a valuation reassessment despite recent gains; investors are revisiting multiples and growth assumptions after mixed short-term returns. Yahoo: Valuation assessment
• Neutral Sentiment: Recent MarketBeat coverage notes a modest dividend increase and a range of analyst target revisions — supportive but incremental to valuation — with consensus still in the moderate-buy area. MarketBeat: Analyst notes & dividend
• Negative Sentiment: Regeneron director Huda Zoghbi sold 1,638 shares (~49% reduction of her holding) in a disclosed transaction; while insider sales are common and may be for personal reasons, large disclosed sales can create short-term selling pressure or raise governance questions for some investors. American Banking News: Insider sale

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.